首页 > 最新文献

Journal of molecular and cellular cardiology最新文献

英文 中文
TFPI2 hypermethylation promotes diabetic atherosclerosis progression through the Ap2α/PPARγ axis TFPI2高甲基化通过Ap2α/PPARγ轴促进糖尿病动脉粥样硬化进展。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/j.yjmcc.2024.11.010
Zongyi Xia , Chi Zhou , Yefeng Hong , Fuhai Li , Wenzhong Zhang , Hongwei Ji , Yu Xiao , Shifang Li , Shufa Li , Xiaohong Lu , Shaohua Li , Kai Tan , Hui Xin , Zhaoyang Wang , Zhenxun Lian , Mengqi Guo
Diabetes mellitus significantly escalates the risk of accelerated atherosclerosis (AS), severely affecting cardiovascular health. Our research, leveraging Gene Expression Omnibus (GEO) database analysis (GSE118481), revealed diminished TFPI2 expression in diabetic patients' atherosclerotic plaques. Further validation in carotid artery plaques and an AS mouse model confirmed TFPI2's reduced expression in diabetes. Through TFPI2 knockdown in non-diabetic mice, we observed aggravated plaque burden and increased inflammatory M1 macrophage polarization. Conversely, TFPI2 overexpression in diabetic mice improved plaque stability and induced reparative M2 macrophage polarization, countering hyperglycemia's negative effects. Mechanistically, transcription factor activator protein 2α (AP-2α) is a repressor of PPPARg transcription, and the interaction of TFPI2 with the transcription factor AP-2α blocks AP-2α binding to the PPARγ gene promoter, which is essential for PPARγ-mediated transcription and the transition from M1 to M2 macrophages. Additionally, hyperglycemia-induced DNA methyltransferase 1 (DNMT1) upregulation heightens TFPI2 methylation, reducing its expression. Our findings spotlight the TFPI2/AP-2α/PPARγ axis as crucial in diabetic AS modulation, proposing its targeting as a new therapeutic strategy to halt diabetes-driven AS progression, highlighting TFPI2's therapeutic promise in addressing diabetes-related cardiovascular issues.
糖尿病显著增加加速动脉粥样硬化(AS)的风险,严重影响心血管健康。我们的研究,利用基因表达综合(GEO)数据库分析(GSE118481),揭示了TFPI2在糖尿病患者动脉粥样硬化斑块中的表达降低。在颈动脉斑块和AS小鼠模型中的进一步验证证实了TFPI2在糖尿病中的表达降低。通过在非糖尿病小鼠中敲低TFPI2,我们观察到斑块负担加重,炎性M1巨噬细胞极化增加。相反,糖尿病小鼠中TFPI2过表达可改善斑块稳定性,诱导修复性M2巨噬细胞极化,抵消高血糖的负面影响。从机制上讲,转录因子激活蛋白2α (AP-2α)是PPPARg转录的抑制因子,TFPI2与转录因子AP-2α的相互作用阻断AP-2α与ppparγ基因启动子的结合,这是ppparγ介导的转录和从M1到M2的巨噬细胞转化所必需的。此外,高血糖诱导的DNA甲基转移酶1 (DNMT1)上调会增加TFPI2甲基化,降低其表达。我们的研究结果表明,TFPI2/AP-2α/PPARγ轴在糖尿病as调节中起着至关重要的作用,提出了其作为一种新的治疗策略来阻止糖尿病驱动的as进展,强调了TFPI2在解决糖尿病相关心血管问题方面的治疗前景。
{"title":"TFPI2 hypermethylation promotes diabetic atherosclerosis progression through the Ap2α/PPARγ axis","authors":"Zongyi Xia ,&nbsp;Chi Zhou ,&nbsp;Yefeng Hong ,&nbsp;Fuhai Li ,&nbsp;Wenzhong Zhang ,&nbsp;Hongwei Ji ,&nbsp;Yu Xiao ,&nbsp;Shifang Li ,&nbsp;Shufa Li ,&nbsp;Xiaohong Lu ,&nbsp;Shaohua Li ,&nbsp;Kai Tan ,&nbsp;Hui Xin ,&nbsp;Zhaoyang Wang ,&nbsp;Zhenxun Lian ,&nbsp;Mengqi Guo","doi":"10.1016/j.yjmcc.2024.11.010","DOIUrl":"10.1016/j.yjmcc.2024.11.010","url":null,"abstract":"<div><div>Diabetes mellitus significantly escalates the risk of accelerated atherosclerosis (AS), severely affecting cardiovascular health. Our research, leveraging Gene Expression Omnibus (GEO) database analysis (GSE118481), revealed diminished TFPI2 expression in diabetic patients' atherosclerotic plaques. Further validation in carotid artery plaques and an AS mouse model confirmed TFPI2's reduced expression in diabetes. Through TFPI2 knockdown in non-diabetic mice, we observed aggravated plaque burden and increased inflammatory M1 macrophage polarization. Conversely, TFPI2 overexpression in diabetic mice improved plaque stability and induced reparative M2 macrophage polarization, countering hyperglycemia's negative effects. Mechanistically, transcription factor activator protein 2α (AP-2α) is a repressor of PPPARg transcription, and the interaction of TFPI2 with the transcription factor AP-2α blocks AP-2α binding to the PPARγ gene promoter, which is essential for PPARγ-mediated transcription and the transition from M1 to M2 macrophages. Additionally, hyperglycemia-induced DNA methyltransferase 1 (DNMT1) upregulation heightens TFPI2 methylation, reducing its expression. Our findings spotlight the TFPI2/AP-2α/PPARγ axis as crucial in diabetic AS modulation, proposing its targeting as a new therapeutic strategy to halt diabetes-driven AS progression, highlighting TFPI2's therapeutic promise in addressing diabetes-related cardiovascular issues.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 45-59"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FSTL1 protects against acute aortic dissection by suppressing vascular smooth muscle cell phenotypic switching and degradation of the extracellular matrix FSTL1通过抑制血管平滑肌细胞表型转换和细胞外基质降解来防止急性主动脉夹层。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/j.yjmcc.2024.11.008
Jun-ping Li , Wan-bing He , Shu-wan Xu , Juan-zhang Liu , Zhao-qi Huang , Chang-ping Li , Chun-ling Huang , Pei-biao Mai , Deng-feng Geng , Xiao-fu Qiu , Zhao-yu Liu , Kun Zhang , Shu-xian Zhou
Acute aortic dissection (AAD) is a life-threatening cardiovascular emergency, which is closely related to the vascular smooth muscle cells (VSMCs) phenotypic switching and extracellular matrix (ECM) degradation. Previous studies have found that the secreted extracellular glycoprotein Follistatin-like 1 (FSTL1) is demonstrated as a protective factor for cardiovascular diseases. However, the role of FSTL1 in AAD remains elusive. We aimed to investigate whether FSTL1 could regulate VSMCs phenotypic switching and ECM degradation in AAD. Firstly, we found that FSTL1 expression in aorta was significantly decreased in human AAD examined by western blot and immunohistochemical staining. Then we established a mouse AAD model by administering β-aminopropionitrile (BAPN) dissolved in drinking water for 28 days. We found that FSTL1 expression in aorta was also decreased in mouse AAD. Exogenous supplement with recombinant human FSTL1 protein could rescue VSMCs phenotypic switching and ECM degradation to reduce the occurrence and progression of mouse AAD. In vitro, FSTL1 protein and adenovirus overexpressing FSTL1 (ad-FSTL1) reversed the primary VSMCs phenotypic switching and decreased the expression of MMP2 induced by PDGF-BB. Knocking down FSTL1 initiates VSMCs phenotypic switching and increases the expression of MMP2. In terms of mechanisms, AMPK phosphorylation was decreased and could be improved by FSTL1 protein in mouse AAD. FSTL1 protein and ad-FSTL1 reversed the decreased AMPK phosphorylation induced by PDGF-BB in primary VSMCs. These findings indicate that FSTL1 protects against VSMCs phenotypic switching and ECM degradation in AAD, and targeting FSTL1 may be a potential new strategy for prevention and treatment of AAD.
急性主动脉夹层(AAD)是一种危及生命的心血管急症,与血管平滑肌细胞(VSMCs)表型转换和细胞外基质(ECM)降解密切相关。先前的研究发现分泌的细胞外糖蛋白卵泡抑素样1 (FSTL1)被证明是心血管疾病的保护因子。然而,FSTL1在AAD中的作用尚不明确。我们的目的是研究FSTL1是否可以调节AAD的VSMCs表型转换和ECM降解。首先,通过western blot和免疫组化染色,我们发现AAD患者主动脉中FSTL1的表达明显降低。然后给药于饮用水中溶解β-氨基丙腈(BAPN) 28 d,建立小鼠AAD模型。我们发现AAD小鼠主动脉FSTL1表达也降低。外源性补充重组人FSTL1蛋白可以挽救VSMCs的表型转换和ECM降解,从而减少小鼠AAD的发生和进展。在体外,FSTL1蛋白和过表达FSTL1的腺病毒(ad-FSTL1)逆转了PDGF-BB诱导的原发性VSMCs表型转换,降低了MMP2的表达。敲低FSTL1启动VSMCs表型转换,增加MMP2的表达。在机制上,小鼠AAD中,AMPK磷酸化水平降低,FSTL1蛋白可改善AMPK磷酸化水平。FSTL1蛋白和ad-FSTL1逆转了PDGF-BB诱导的原发性VSMCs中AMPK磷酸化的下降。这些研究结果表明,FSTL1可以防止AAD中VSMCs表型转换和ECM降解,靶向FSTL1可能是预防和治疗AAD的潜在新策略。
{"title":"FSTL1 protects against acute aortic dissection by suppressing vascular smooth muscle cell phenotypic switching and degradation of the extracellular matrix","authors":"Jun-ping Li ,&nbsp;Wan-bing He ,&nbsp;Shu-wan Xu ,&nbsp;Juan-zhang Liu ,&nbsp;Zhao-qi Huang ,&nbsp;Chang-ping Li ,&nbsp;Chun-ling Huang ,&nbsp;Pei-biao Mai ,&nbsp;Deng-feng Geng ,&nbsp;Xiao-fu Qiu ,&nbsp;Zhao-yu Liu ,&nbsp;Kun Zhang ,&nbsp;Shu-xian Zhou","doi":"10.1016/j.yjmcc.2024.11.008","DOIUrl":"10.1016/j.yjmcc.2024.11.008","url":null,"abstract":"<div><div>Acute aortic dissection (AAD) is a life-threatening cardiovascular emergency, which is closely related to the vascular smooth muscle cells (VSMCs) phenotypic switching and extracellular matrix (ECM) degradation. Previous studies have found that the secreted extracellular glycoprotein Follistatin-like 1 (FSTL1) is demonstrated as a protective factor for cardiovascular diseases. However, the role of FSTL1 in AAD remains elusive. We aimed to investigate whether FSTL1 could regulate VSMCs phenotypic switching and ECM degradation in AAD. Firstly, we found that FSTL1 expression in aorta was significantly decreased in human AAD examined by western blot and immunohistochemical staining. Then we established a mouse AAD model by administering β-aminopropionitrile (BAPN) dissolved in drinking water for 28 days. We found that FSTL1 expression in aorta was also decreased in mouse AAD. Exogenous supplement with recombinant human FSTL1 protein could rescue VSMCs phenotypic switching and ECM degradation to reduce the occurrence and progression of mouse AAD. <em>In vitro</em>, FSTL1 protein and adenovirus overexpressing FSTL1 (ad-FSTL1) reversed the primary VSMCs phenotypic switching and decreased the expression of MMP2 induced by PDGF-BB. Knocking down FSTL1 initiates VSMCs phenotypic switching and increases the expression of MMP2. In terms of mechanisms, AMPK phosphorylation was decreased and could be improved by FSTL1 protein in mouse AAD. FSTL1 protein and ad-FSTL1 reversed the decreased AMPK phosphorylation induced by PDGF-BB in primary VSMCs. These findings indicate that FSTL1 protects against VSMCs phenotypic switching and ECM degradation in AAD, and targeting FSTL1 may be a potential new strategy for prevention and treatment of AAD.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 60-73"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congratulations to our Top Papers of 2024
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/S0022-2828(24)00222-0
{"title":"Congratulations to our Top Papers of 2024","authors":"","doi":"10.1016/S0022-2828(24)00222-0","DOIUrl":"10.1016/S0022-2828(24)00222-0","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Page iii"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recognizing outstanding reviewers for JMCC in 2024
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/S0022-2828(24)00223-2
{"title":"Recognizing outstanding reviewers for JMCC in 2024","authors":"","doi":"10.1016/S0022-2828(24)00223-2","DOIUrl":"10.1016/S0022-2828(24)00223-2","url":null,"abstract":"","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Page iv"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MMP-2 inhibition attenuates ER stress-mediated cell death during myocardial ischemia-reperfusion injury by preserving IRE1α 抑制MMP-2可通过保留IRE1α来减轻心肌缺血再灌注损伤时内质网应激介导的细胞死亡。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/j.yjmcc.2024.11.013
Wesam Bassiouni , Zabed Mahmud , Thomas Simmen , John M. Seubert , Richard Schulz
Endoplasmic reticulum (ER) stress is one of the major events accompanying myocardial ischemia-reperfusion (IR) injury, as hypoxia and oxidative stress disrupt protein folding in the ER. As a result, the unfolded protein response (UPR) is activated through different sensors including inositol-requiring enzyme 1α (IRE1α) and protein kinase R-like ER kinase (PERK). Failure of the UPR to reduce ER stress induces cellular dysfunction. Matrix metalloproteinase-2 (MMP-2) is a ubiquitous protease that is activated intracellularly in response to oxidative stress and partially localizes near the ER. However, its role in ER homeostasis is unknown. We hypothesized that MMP-2 is involved in the regulation of the UPR and ER stress-mediated apoptosis during IR injury. Isolated mouse hearts subjected to IR injury showed impaired recovery of post-ischemic contractile function compared to aerobically perfused controls. Ventricular extracts from IR hearts had higher levels of glucose-regulated protein-78 and protein disulfide isomerase and lower levels of IRE1α and PERK compared to aerobic controls. MMP-2 inhibitors, ARP-100 or ONO-4817, given 10 min before ischemia, improved cardiac post-ischemic recovery and preserved IRE1α level in hearts subjected to 30 min ischemia/40 min reperfusion. IR also increased the levels of CHOP and mitochondrial Bax and caspase-3 and -9 activities, indicating induction of apoptosis, all of which were attenuated by MMP-2 inhibitors, regardless of the reperfusion time. Immunoprecipitation showed an association between MMP-2 and IRE1α in aerobic and IR hearts. During myocardial IR injury MMP-2 may impair the UPR and induce apoptosis by proteolysis of IRE1α. Inhibition of MMP-2 activity protects against cardiac contractile dysfunction in part by preserving IRE1α and preventing the progression to myocardial cell death.
内质网(ER)应激是心肌缺血再灌注(IR)损伤的主要事件之一,因为缺氧和氧化应激破坏了内质网中的蛋白质折叠。因此,未折叠蛋白反应(UPR)通过不同的传感器被激活,包括肌醇要求酶1α (IRE1α)和蛋白激酶r样ER激酶(PERK)。UPR减少内质网应激的失败会导致细胞功能障碍。基质金属蛋白酶-2 (Matrix metalloproteinase-2, MMP-2)是一种普遍存在的蛋白酶,在细胞内响应氧化应激时被激活,部分定位于内质网附近。然而,其在内质网稳态中的作用尚不清楚。我们假设MMP-2参与了IR损伤中UPR和内质网应激介导的细胞凋亡的调控。与有氧灌注对照相比,受IR损伤的离体小鼠心脏显示缺血后收缩功能的恢复受损。与有氧对照相比,IR心脏的心室提取物具有更高水平的葡萄糖调节蛋白-78和蛋白二硫异构酶,以及更低水平的IRE1α和PERK。MMP-2抑制剂,ARP-100或ONO-4817,在缺血前10 min给予,改善心脏缺血后恢复,并保持心脏缺血30 min /再灌注40 min的IRE1α水平。IR还增加了CHOP和线粒体Bax的水平以及caspase-3和-9的活性,表明诱导了细胞凋亡,而这些都被MMP-2抑制剂减弱,与再灌注时间无关。免疫沉淀显示有氧和IR心脏中MMP-2和IRE1α之间存在关联。在心肌IR损伤过程中,MMP-2可能通过IRE1α的蛋白水解而影响UPR并诱导凋亡。抑制MMP-2活性部分通过保留IRE1α和防止心肌细胞死亡的进展来保护心脏收缩功能障碍。
{"title":"MMP-2 inhibition attenuates ER stress-mediated cell death during myocardial ischemia-reperfusion injury by preserving IRE1α","authors":"Wesam Bassiouni ,&nbsp;Zabed Mahmud ,&nbsp;Thomas Simmen ,&nbsp;John M. Seubert ,&nbsp;Richard Schulz","doi":"10.1016/j.yjmcc.2024.11.013","DOIUrl":"10.1016/j.yjmcc.2024.11.013","url":null,"abstract":"<div><div>Endoplasmic reticulum (ER) stress is one of the major events accompanying myocardial ischemia-reperfusion (IR) injury, as hypoxia and oxidative stress disrupt protein folding in the ER. As a result, the unfolded protein response (UPR) is activated through different sensors including inositol-requiring enzyme 1α (IRE1α) and protein kinase R-like ER kinase (PERK). Failure of the UPR to reduce ER stress induces cellular dysfunction. Matrix metalloproteinase-2 (MMP-2) is a ubiquitous protease that is activated intracellularly in response to oxidative stress and partially localizes near the ER. However, its role in ER homeostasis is unknown. We hypothesized that MMP-2 is involved in the regulation of the UPR and ER stress-mediated apoptosis during IR injury. Isolated mouse hearts subjected to IR injury showed impaired recovery of post-ischemic contractile function compared to aerobically perfused controls. Ventricular extracts from IR hearts had higher levels of glucose-regulated protein-78 and protein disulfide isomerase and lower levels of IRE1α and PERK compared to aerobic controls. MMP-2 inhibitors, ARP-100 or ONO-4817, given 10 min before ischemia, improved cardiac post-ischemic recovery and preserved IRE1α level in hearts subjected to 30 min ischemia/40 min reperfusion. IR also increased the levels of CHOP and mitochondrial Bax and caspase-3 and -9 activities, indicating induction of apoptosis, all of which were attenuated by MMP-2 inhibitors, regardless of the reperfusion time. Immunoprecipitation showed an association between MMP-2 and IRE1α in aerobic and IR hearts. During myocardial IR injury MMP-2 may impair the UPR and induce apoptosis by proteolysis of IRE1α. Inhibition of MMP-2 activity protects against cardiac contractile dysfunction in part by preserving IRE1α and preventing the progression to myocardial cell death.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 74-88"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-specific hiPSC-derived cardiomyocytes indicate allelic and contractile imbalance as pathogenic factor in early-stage Hypertrophic Cardiomyopathy 患者特异性hipsc衍生的心肌细胞表明等位基因和收缩失衡是早期肥厚性心肌病的致病因素。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/j.yjmcc.2024.11.007
Natalie Weber , Judith Montag , Kathrin Kowalski , Bogdan Iorga , Jeanne de la Roche , Tim Holler , Daniel Wojciechowski , Meike Wendland , Ante Radocaj , Anne-Kathrin Mayer , Anja Brunkhorst , Felix Osten , Valentin Burkart , Birgit Piep , Alea Bodenschatz , Pia Gibron , Kristin Schwanke , Annika Franke , Stefan Thiemann , Anastasia Koroleva , Theresia Kraft
Hypertrophic Cardiomyopathy (HCM) is often caused by heterozygous mutations in β-myosin heavy chain (MYH7, β-MyHC). In addition to hyper- or hypocontractile effects of HCM-mutations, heterogeneity in contractile function (contractile imbalance) among individual cardiomyocytes was observed in end-stage HCM-myocardium. Contractile imbalance might be induced by burst-like transcription, leading to unequal fractions of mutant versus wildtype mRNA and protein in individual cardiomyocytes (allelic imbalance). Until now it is not known if allelic and contractile imbalance are present early in HCM-development or rather occur in response to disease-associated remodeling.
To address this question, we used patient-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with heterozygous MYH7-mutations R723G and G741R as models of early-stage HCM without secondary adaptions upon disease progression. R723G-hiPSC-CMs showed typical HCM-markers like hypertrophy and myofibrillar disarray. Using RNA-FISH and allele-specific single-cell-PCR, we show for both cell lines that MYH7 is transcribed in bursts. Highly variable mutant vs. wildtype MYH7-mRNA fractions in individual HCM-hiPSC-CMs indicated allelic imbalance. HCM-hiPSC-CM-lines showed functional alterations like slowed twitch contraction kinetics and reduced calcium sensitivity of myofibrillar force generation. A significantly larger variability in force generation or twitch parameters of individual HCM-hiPSC-CMs compared to WT-hiPSC-CMs indicated contractile imbalance.
Our results with early-stage hiPSC-CMs strongly suggest that burst-like transcription and allelic imbalance are general features of CMs, which together with mutation-induced changes of sarcomere contraction could induce contractile imbalance in heterozygous CMs, presumably aggravating development of HCM. Genetic or epigenetic approaches targeting functional heterogeneity in HCM could lead to promising future therapies, in addition to myosin modulation.
肥厚性心肌病(HCM)通常由β-肌球蛋白重链(MYH7, β-MyHC)的杂合突变引起。在终末期hcm -心肌中,除了hcm -突变的高收缩或低收缩效应外,单个心肌细胞之间的收缩功能(收缩失衡)也存在异质性。收缩性失衡可能是由突发性转录引起的,导致个体心肌细胞中突变型与野生型mRNA和蛋白质的比例不相等(等位基因失衡)。到目前为止,尚不清楚等位基因和收缩失衡是否在hcm发育早期出现,或者更确切地说,是在对疾病相关重塑的反应中发生。为了解决这个问题,我们使用具有myh7杂合突变R723G和G741R的患者特异性人诱导多能干细胞衍生的心肌细胞(hiPSC-CMs)作为早期HCM模型,在疾病进展中没有继发性适应。R723G-hiPSC-CMs表现出典型的hcm标记,如肥厚和肌纤维紊乱。使用RNA-FISH和等位基因特异性单细胞pcr,我们发现在这两种细胞系中MYH7都是在爆发中转录的。个体HCM-hiPSC-CMs中高度可变的突变型与野生型MYH7-mRNA片段表明等位基因失衡。hcm - hipsc - cm系表现出肌纤维收缩动力学减慢和肌纤维力产生的钙敏感性降低等功能改变。与WT-hiPSC-CMs相比,单个HCM-hiPSC-CMs的力产生或抽搐参数的变异性明显更大,表明收缩不平衡。我们对早期hiPSC-CMs的研究结果强烈表明,突发性转录和等位基因失衡是CMs的普遍特征,这些特征与突变诱导的肌瘤收缩改变一起可能导致杂合CMs的收缩失衡,从而可能加剧HCM的发展。除了肌球蛋白调节外,针对HCM功能异质性的遗传学或表观遗传学方法可能会带来有希望的未来治疗方法。
{"title":"Patient-specific hiPSC-derived cardiomyocytes indicate allelic and contractile imbalance as pathogenic factor in early-stage Hypertrophic Cardiomyopathy","authors":"Natalie Weber ,&nbsp;Judith Montag ,&nbsp;Kathrin Kowalski ,&nbsp;Bogdan Iorga ,&nbsp;Jeanne de la Roche ,&nbsp;Tim Holler ,&nbsp;Daniel Wojciechowski ,&nbsp;Meike Wendland ,&nbsp;Ante Radocaj ,&nbsp;Anne-Kathrin Mayer ,&nbsp;Anja Brunkhorst ,&nbsp;Felix Osten ,&nbsp;Valentin Burkart ,&nbsp;Birgit Piep ,&nbsp;Alea Bodenschatz ,&nbsp;Pia Gibron ,&nbsp;Kristin Schwanke ,&nbsp;Annika Franke ,&nbsp;Stefan Thiemann ,&nbsp;Anastasia Koroleva ,&nbsp;Theresia Kraft","doi":"10.1016/j.yjmcc.2024.11.007","DOIUrl":"10.1016/j.yjmcc.2024.11.007","url":null,"abstract":"<div><div>Hypertrophic Cardiomyopathy (HCM) is often caused by heterozygous mutations in β-myosin heavy chain (<em>MYH7</em>, β-MyHC). In addition to hyper- or hypocontractile effects of HCM-mutations, heterogeneity in contractile function (<em>contractile imbalance</em>) among individual cardiomyocytes was observed in end-stage HCM-myocardium. <em>Contractile imbalance</em> might be induced by burst-like transcription, leading to unequal fractions of mutant versus wildtype mRNA and protein in individual cardiomyocytes (allelic imbalance). Until now it is not known if allelic and <em>contractile imbalance</em> are present early in HCM-development or rather occur in response to disease-associated remodeling.</div><div>To address this question, we used patient-specific human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with heterozygous <em>MYH7</em>-mutations R723G and G741R as models of early-stage HCM without secondary adaptions upon disease progression. R723G-hiPSC-CMs showed typical HCM-markers like hypertrophy and myofibrillar disarray. Using RNA-FISH and allele-specific single-cell-PCR, we show for both cell lines that <em>MYH7</em> is transcribed in bursts. Highly variable mutant vs. wildtype <em>MYH7</em>-mRNA fractions in individual HCM-hiPSC-CMs indicated allelic imbalance. HCM-hiPSC-CM-lines showed functional alterations like slowed twitch contraction kinetics and reduced calcium sensitivity of myofibrillar force generation. A significantly larger variability in force generation or twitch parameters of individual HCM-hiPSC-CMs compared to WT-hiPSC-CMs indicated <em>contractile imbalance</em>.</div><div>Our results with early-stage hiPSC-CMs strongly suggest that burst-like transcription and allelic imbalance are general features of CMs, which together with mutation-induced changes of sarcomere contraction could induce <em>contractile imbalance</em> in heterozygous CMs, presumably aggravating development of HCM. Genetic or epigenetic approaches targeting functional heterogeneity in HCM could lead to promising future therapies, in addition to myosin modulation.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 112-125"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibition of miR-92a normalizes vascular gene expression and prevents diastolic dysfunction in heart failure with preserved ejection fraction 抑制 miR-92a 可使射血分数保留型心力衰竭患者的血管基因表达正常化并预防舒张功能障碍。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/j.yjmcc.2024.11.004
Badder Kattih , Ariane Fischer , Marion Muhly-Reinholz , Lukas Tombor , Luka Nicin , Sebastian Cremer , Andreas M. Zeiher , David John , Wesley Tyler Abplanalp , Stefanie Dimmeler
Heart failure with preserved ejection fraction (HFpEF) remains a major public health burden with increasing prevalence but only few effective therapies. Endothelial dysfunction and inflammation are identified as pathophysiological drivers of HFpEF disease progression. MicroRNAs are increasingly recognized as key regulators of these pathological processes, while antimiR-based therapies have been emerged as promising therapeutics in mice and humans. Therefore, we tested whether miR-92a-3p inhibition is a promising therapeutic intervention to target HFpEF in vivo.
By injection of locked nucleic acid (LNA)-based antimiR (LNA-92a) weekly, we demonstrate that inhibition of miR-92a-3p attenuates the development of diastolic dysfunction and left atrial dilation following experimental induction of HFpEF in mice. Indeed, LNA-92a depleted miR-92a-3p expression in the myocardium and peripheral blood, and derepressed predicted target genes in a cell type-specific manner. Furthermore, cell-type specific efficacy of LNA-92a treatment was assessed by single-nuclear RNA sequencing of HFpEF hearts either treated with LNA-92a or LNA-Control. Endothelial cells of LNA-92a treated mice showed normalized vascular gene expression and reduced gene signatures associated with endothelial-mesenchymal transition.

Conclusion

This study demonstrates that LNA-based antimiR-92a is an effective therapeutic strategy to target diastolic dysfunction and left atrial dilation in HFpEF.
射血分数保留型心力衰竭(HFpEF)仍然是一项重大的公共卫生负担,其发病率不断上升,但有效的治疗方法却寥寥无几。内皮功能障碍和炎症被认为是 HFpEF 疾病进展的病理生理学驱动因素。人们越来越认识到,微RNA是这些病理过程的关键调控因子,而基于抗miR的疗法已在小鼠和人类中成为有前景的疗法。因此,我们测试了以抑制 miR-92a-3p 为靶点是否是一种有前景的体内 HFpEF 治疗干预方法。通过每周注射基于锁定核酸(LNA)的抗miR(LNA-92a),我们证明抑制miR-92a-3p可减轻实验性诱导小鼠HFpEF后舒张功能障碍和左心房扩张的发展。事实上,LNA-92a 会消耗 miR-92a-3p 在心肌和外周血中的表达,并以细胞类型特异性的方式抑制预测的靶基因。此外,通过对接受 LNA-92a 或 LNA-Control 治疗的 HFpEF 心脏进行单核 RNA 测序,评估了 LNA-92a 治疗的细胞特异性功效。LNA-92a 治疗小鼠的内皮细胞显示血管基因表达正常化,与内皮-间质转化相关的基因特征减少。结论:本研究表明,基于 LNA 的抗 R-92a 是针对高频心衰患者舒张功能障碍和左心房扩张的有效治疗策略。
{"title":"Inhibition of miR-92a normalizes vascular gene expression and prevents diastolic dysfunction in heart failure with preserved ejection fraction","authors":"Badder Kattih ,&nbsp;Ariane Fischer ,&nbsp;Marion Muhly-Reinholz ,&nbsp;Lukas Tombor ,&nbsp;Luka Nicin ,&nbsp;Sebastian Cremer ,&nbsp;Andreas M. Zeiher ,&nbsp;David John ,&nbsp;Wesley Tyler Abplanalp ,&nbsp;Stefanie Dimmeler","doi":"10.1016/j.yjmcc.2024.11.004","DOIUrl":"10.1016/j.yjmcc.2024.11.004","url":null,"abstract":"<div><div>Heart failure with preserved ejection fraction (HFpEF) remains a major public health burden with increasing prevalence but only few effective therapies. Endothelial dysfunction and inflammation are identified as pathophysiological drivers of HFpEF disease progression. MicroRNAs are increasingly recognized as key regulators of these pathological processes, while antimiR-based therapies have been emerged as promising therapeutics in mice and humans. Therefore, we tested whether miR-92a-3p inhibition is a promising therapeutic intervention to target HFpEF in vivo.</div><div>By injection of locked nucleic acid (LNA)-based antimiR (LNA-92a) weekly, we demonstrate that inhibition of miR-92a-3p attenuates the development of diastolic dysfunction and left atrial dilation following experimental induction of HFpEF in mice. Indeed, LNA-92a depleted miR-92a-3p expression in the myocardium and peripheral blood, and derepressed predicted target genes in a cell type-specific manner. Furthermore, cell-type specific efficacy of LNA-92a treatment was assessed by single-nuclear RNA sequencing of HFpEF hearts either treated with LNA-92a or LNA-Control. Endothelial cells of LNA-92a treated mice showed normalized vascular gene expression and reduced gene signatures associated with endothelial-mesenchymal transition.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that LNA-based antimiR-92a is an effective therapeutic strategy to target diastolic dysfunction and left atrial dilation in HFpEF.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 89-98"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner 钠/葡萄糖共转运蛋白2抑制剂恩格列净以突变特异性的方式抑制长QT 3晚期钠电流。
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1016/j.yjmcc.2024.11.014
Lynn C. Lunsonga , Mohammad Fatehi , Wentong Long , Amy J. Barr , Brittany Gruber , Arkapravo Chattopadhyay , Khaled Barakat , Andrew G. Edwards , Peter E. Light

Background

Sodium/glucose cotransporter 2 inhibitors (SGLT2is) like empagliflozin have demonstrated cardioprotective effects in patients with or without diabetes. SGLT2is have been shown to selectively inhibit the late component of cardiac sodium current (late INa). Induction of late INa is the primary mechanism in the pathophysiology of congenital long QT syndrome type 3 (LQT3) gain-of-function mutations in the SCN5A gene encoding Nav1.5. We investigated empagliflozin's effect on late INa in thirteen known LQT3 mutations located in distinct regions of the channel.

Methods

The whole-cell patch-clamp technique was used to investigate the effect of empagliflozin on late INa in recombinantly expressed Nav1.5 channels containing different LQT3 mutations. Molecular modeling of human Nav1.5 and simulations in a mathematical model of human ventricular myocytes were used to extrapolate our experimental results to excitation-contraction coupling.

Results

Empagliflozin selectively inhibited late INa in LQT3 mutations in the inactivation gate region of Nav1.5, without affecting peak current or channel kinetics. In contrast, empagliflozin inhibited both peak and late INa in mutations in the S4 voltage-sensing regions, altered channel gating, and slowed recovery from inactivation. Empagliflozin had no effect on late/peak INa or channel kinetics in channels with mutations in the putative empagliflozin binding region. Simulation results predict that empagliflozin may have a desirable therapeutic effect in LQT3 mutations in the inactivation gate region.

Conclusions

Empagliflozin selectively inhibits late INa, without affecting channel kinetics, in LQT3 mutations in the inactivation gate region. Empagliflozin may thus be a promising precision medicine approach for patients with specific LQT3 mutations.
背景:钠/葡萄糖共转运蛋白2抑制剂(SGLT2is)如恩格列净已被证明对糖尿病患者或非糖尿病患者具有心脏保护作用。SGLT2is已被证明有选择性地抑制心脏钠电流的晚期成分(晚期INa)。晚期INa的诱导是先天性长QT综合征3型(LQT3)编码Nav1.5的SCN5A基因功能获得性突变的病理生理学的主要机制。我们研究了恩格列净对位于通道不同区域的13个已知LQT3突变的晚期INa的影响。方法:采用全细胞膜片钳技术研究依帕列净对不同LQT3突变的重组表达Nav1.5通道晚期INa的影响。利用人Nav1.5的分子模型和人心室肌细胞的数学模型进行模拟,将实验结果推断为兴奋-收缩耦合。结果:恩格列净选择性抑制Nav1.5失活门区LQT3突变的晚期INa,不影响峰值电流或通道动力学。相比之下,恩格列净抑制了S4电压感应区突变的峰值和晚期INa,改变了通道门控,减缓了失活后的恢复。依帕列净对假定的依帕列净结合区突变的通道的晚期/峰值INa或通道动力学没有影响。模拟结果预测,恩格列净可能对失活门区LQT3突变具有理想的治疗效果。结论:恩帕列净选择性抑制晚期INa,不影响通道动力学,在LQT3失活门区突变。因此,恩帕列净可能是一种有希望的精准医疗方法,用于特定LQT3突变的患者。
{"title":"The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner","authors":"Lynn C. Lunsonga ,&nbsp;Mohammad Fatehi ,&nbsp;Wentong Long ,&nbsp;Amy J. Barr ,&nbsp;Brittany Gruber ,&nbsp;Arkapravo Chattopadhyay ,&nbsp;Khaled Barakat ,&nbsp;Andrew G. Edwards ,&nbsp;Peter E. Light","doi":"10.1016/j.yjmcc.2024.11.014","DOIUrl":"10.1016/j.yjmcc.2024.11.014","url":null,"abstract":"<div><h3>Background</h3><div>Sodium/glucose cotransporter 2 inhibitors (SGLT2is) like empagliflozin have demonstrated cardioprotective effects in patients with or without diabetes. SGLT2is have been shown to selectively inhibit the late component of cardiac sodium current (late I<sub>Na</sub>). Induction of late I<sub>Na</sub> is the primary mechanism in the pathophysiology of congenital long QT syndrome type 3 (LQT3) gain-of-function mutations in the SCN5A gene encoding Nav1.5. We investigated empagliflozin's effect on late I<sub>Na</sub> in thirteen known LQT3 mutations located in distinct regions of the channel.</div></div><div><h3>Methods</h3><div>The whole-cell patch-clamp technique was used to investigate the effect of empagliflozin on late I<sub>Na</sub> in recombinantly expressed Nav1.5 channels containing different LQT3 mutations. Molecular modeling of human Nav1.5 and simulations in a mathematical model of human ventricular myocytes were used to extrapolate our experimental results to excitation-contraction coupling.</div></div><div><h3>Results</h3><div>Empagliflozin selectively inhibited late I<sub>Na</sub> in LQT3 mutations in the inactivation gate region of Nav1.5, without affecting peak current or channel kinetics. In contrast, empagliflozin inhibited both peak and late I<sub>Na</sub> in mutations in the S4 voltage-sensing regions, altered channel gating, and slowed recovery from inactivation. Empagliflozin had no effect on late/peak I<sub>Na</sub> or channel kinetics in channels with mutations in the putative empagliflozin binding region. Simulation results predict that empagliflozin may have a desirable therapeutic effect in LQT3 mutations in the inactivation gate region.</div></div><div><h3>Conclusions</h3><div>Empagliflozin selectively inhibits late I<sub>Na</sub>, without affecting channel kinetics, in LQT3 mutations in the inactivation gate region. Empagliflozin may thus be a promising precision medicine approach for patients with specific LQT3 mutations.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 99-111"},"PeriodicalIF":4.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clockwork conditioning: Aligning the skeletal muscle clock with time-of-day exercise for cardiometabolic health 时钟调节:调整骨骼肌时钟与心脏代谢健康的日常锻炼时间
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-29 DOI: 10.1016/j.yjmcc.2024.11.011
Spencer B. Procopio, Karyn A. Esser
Circadian rhythms have evolved to synchronize gene expression, physiology, and behavior with time-of-day changes in the external environment. In every mammalian cell exists a core clock mechanism that consists of a transcriptional-translational feedback loop that drives rhythmic gene expression. Circadian disruption, as observed in shift workers and genetic mouse models, contributes to the onset and progression of cardiometabolic disorders. The central clock, located in the hypothalamus, is uniquely sensitive to external light cues, while the peripheral clocks are responsive to non-photic stimuli such as feeding and activity in addition to signals from the central clock. Recent research has illustrated the sensitivity of the skeletal muscle circadian clock to exercise timing, offering a promising avenue for therapeutic intervention in cardiometabolic health. Here we provide an in-depth examination of the molecular mechanisms underlying skeletal muscle clock function and its impact on cardiometabolic pathways, including glucose and lipid metabolism, as well as inflammation. To highlight the role of exercise as a time-cue for the skeletal muscle clock, we discuss evidence of exercise-induced shifts in the skeletal muscle clock and the differential response to exercise performed at different times of the day. Furthermore, we present data in support of time-of-day exercise as a potential therapeutic strategy for mitigating cardiometabolic disease burden. By exploring the relationship between the skeletal muscle clock, exercise timing, and cardiometabolic health, we identify new areas for future research and offer valuable insights into novel therapeutic approaches aimed at improving cardiometabolic disease outcomes.
昼夜节律已经进化到使基因表达、生理和行为与外部环境的时间变化同步。在每一个哺乳动物细胞中都存在一个由转录-翻译反馈回路组成的核心时钟机制,该机制驱动有节奏的基因表达。在轮班工人和遗传小鼠模型中观察到的昼夜节律中断有助于心脏代谢疾病的发生和进展。位于下丘脑的中央时钟对外部光线信号非常敏感,而外围时钟除了对来自中央时钟的信号外,还对进食和活动等非光刺激做出反应。最近的研究表明,骨骼肌生物钟对运动时间的敏感性,为心脏代谢健康的治疗干预提供了一条有希望的途径。在这里,我们深入研究了骨骼肌时钟功能的分子机制及其对心脏代谢途径的影响,包括葡萄糖和脂质代谢,以及炎症。为了强调运动作为骨骼肌时钟的时间线索的作用,我们讨论了运动引起的骨骼肌时钟变化的证据,以及一天中不同时间对运动的不同反应。此外,我们提供的数据支持每天锻炼作为减轻心脏代谢疾病负担的潜在治疗策略。通过探索骨骼肌时钟、运动时间和心脏代谢健康之间的关系,我们确定了未来研究的新领域,并为旨在改善心脏代谢疾病结果的新治疗方法提供了有价值的见解。
{"title":"Clockwork conditioning: Aligning the skeletal muscle clock with time-of-day exercise for cardiometabolic health","authors":"Spencer B. Procopio,&nbsp;Karyn A. Esser","doi":"10.1016/j.yjmcc.2024.11.011","DOIUrl":"10.1016/j.yjmcc.2024.11.011","url":null,"abstract":"<div><div>Circadian rhythms have evolved to synchronize gene expression, physiology, and behavior with time-of-day changes in the external environment. In every mammalian cell exists a core clock mechanism that consists of a transcriptional-translational feedback loop that drives rhythmic gene expression. Circadian disruption, as observed in shift workers and genetic mouse models, contributes to the onset and progression of cardiometabolic disorders. The central clock, located in the hypothalamus, is uniquely sensitive to external light cues, while the peripheral clocks are responsive to non-photic stimuli such as feeding and activity in addition to signals from the central clock. Recent research has illustrated the sensitivity of the skeletal muscle circadian clock to exercise timing, offering a promising avenue for therapeutic intervention in cardiometabolic health. Here we provide an in-depth examination of the molecular mechanisms underlying skeletal muscle clock function and its impact on cardiometabolic pathways, including glucose and lipid metabolism, as well as inflammation. To highlight the role of exercise as a time-cue for the skeletal muscle clock, we discuss evidence of exercise-induced shifts in the skeletal muscle clock and the differential response to exercise performed at different times of the day. Furthermore, we present data in support of time-of-day exercise as a potential therapeutic strategy for mitigating cardiometabolic disease burden. By exploring the relationship between the skeletal muscle clock, exercise timing, and cardiometabolic health, we identify new areas for future research and offer valuable insights into novel therapeutic approaches aimed at improving cardiometabolic disease outcomes.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 36-44"},"PeriodicalIF":4.9,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyaluronan provokes inflammation but suppresses phagocytotic function in macrophages 透明质酸引起炎症,但抑制巨噬细胞的吞噬功能
IF 4.9 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-29 DOI: 10.1016/j.yjmcc.2024.11.009
Timothy N. Audam , Caitlin M. Howard , Danielle T. Little , Lauren F. Garrett , Yi Wei Zheng , Zhen Gu , Kenneth R. Brittian , Raéden Gray , Julia Chariker , Richa A. Singhal , Marcin Wysoczynski , Steven P. Jones

Background

The extracellular matrix (ECM) provides structural and functional support for the myocardium, but myocardial infarction (MI) changes the composition of the ECM. One of the chief components of the ECM, hyaluronan (HA), accumulates after MI; however, specific biological actions of HA—particularly at the level of infiltrating immune cells and implications of such interactions on ventricular remodeling—have not been explored.

Goal

Because acute accumulation of HA coincides with macrophage infiltration after MI, we assessed the impact of HA on macrophage function.

Results

Compared to SHAM hearts, HA levels were elevated in both the infarct and remote regions of infarcted hearts. Because acute accumulation of HA coincides with macrophage infiltration after MI, we explored the implication of HA accumulation on various endpoints of macrophage function, including macrophage activation, phagocytosis, and efferocytosis. Our data suggests that exposing macrophages to HAHMW pushes macrophages toward a more pro-inflammatory phenotype as indicated by increased secretion of pro-inflammatory signals such as IL-2, IL-17, and IP-10. Our data also suggests that in the presence of HA, both macrophage efferocytosis and Fc-receptor dependent phagocytosis are suppressed. These results are unique to treatment with HAHMW, as similar results were not observed when cells were treated with HALMW. Using macrophages from Cd44−/− mice, we determined that while the impact of HAHMW on cytokine secretion does seem to be dependent in part on Cd44 expression, the impact on macrophage phagocytosis is independent. Since macrophage efferocytosis of dying cardiomyocytes and cellular debris is critical following MI, we believe that this response will prolong the resolution of inflammation and lead to maladaptive remodeling.

Conclusion

HA accumulates post-MI and may promote a pro-inflammatory phenotype in macrophages. Future studies will explore the extent to which post infarct HA accumulation regulates cardiac macrophage dynamics and function in vivo.
细胞外基质(ECM)为心肌提供结构和功能支持,但心肌梗死(MI)改变了细胞外基质的组成。ECM的主要成分之一透明质酸(HA)在心肌梗死后积累;然而,ha的特异性生物学作用——特别是在浸润免疫细胞水平上的作用以及这种相互作用对心室重塑的影响——尚未被探索。由于心肌梗死后HA的急性积累与巨噬细胞浸润一致,我们评估了HA对巨噬细胞功能的影响。结果与假手术心脏相比,HA水平在梗死心脏和梗死心脏的远端区域均升高。由于心肌梗死后HA的急性积累与巨噬细胞浸润相吻合,我们探讨了HA积累对巨噬细胞功能各个终点的影响,包括巨噬细胞活化、吞噬和efferocytosis。我们的数据表明,巨噬细胞暴露于HAHMW会促使巨噬细胞向更亲炎的表型发展,如促炎信号如IL-2、IL-17和IP-10的分泌增加。我们的数据还表明,在HA存在的情况下,巨噬细胞efferocytosis和fc受体依赖性吞噬都受到抑制。这些结果是HAHMW治疗所特有的,因为当细胞用HALMW治疗时没有观察到类似的结果。利用来自Cd44 - / -小鼠的巨噬细胞,我们确定,虽然HAHMW对细胞因子分泌的影响似乎部分依赖于Cd44表达,但对巨噬细胞吞噬的影响是独立的。由于心肌梗死后死亡的心肌细胞和细胞碎片的巨噬细胞efferocysis是至关重要的,我们认为这种反应将延长炎症的消退并导致适应性不良的重塑。结论血凝素在心肌梗死后积累,可能促进巨噬细胞的促炎表型。未来的研究将探索梗死后HA积累在体内调节心脏巨噬细胞动力学和功能的程度。
{"title":"Hyaluronan provokes inflammation but suppresses phagocytotic function in macrophages","authors":"Timothy N. Audam ,&nbsp;Caitlin M. Howard ,&nbsp;Danielle T. Little ,&nbsp;Lauren F. Garrett ,&nbsp;Yi Wei Zheng ,&nbsp;Zhen Gu ,&nbsp;Kenneth R. Brittian ,&nbsp;Raéden Gray ,&nbsp;Julia Chariker ,&nbsp;Richa A. Singhal ,&nbsp;Marcin Wysoczynski ,&nbsp;Steven P. Jones","doi":"10.1016/j.yjmcc.2024.11.009","DOIUrl":"10.1016/j.yjmcc.2024.11.009","url":null,"abstract":"<div><h3>Background</h3><div>The extracellular matrix (ECM) provides structural and functional support for the myocardium, but myocardial infarction (MI) changes the composition of the ECM. One of the chief components of the ECM, hyaluronan (HA), accumulates after MI; however, specific biological actions of HA—particularly at the level of infiltrating immune cells and implications of such interactions on ventricular remodeling—have not been explored.</div></div><div><h3>Goal</h3><div>Because acute accumulation of HA coincides with macrophage infiltration after MI, we assessed the impact of HA on macrophage function.</div></div><div><h3>Results</h3><div>Compared to SHAM hearts, HA levels were elevated in both the infarct and remote regions of infarcted hearts. Because acute accumulation of HA coincides with macrophage infiltration after MI, we explored the implication of HA accumulation on various endpoints of macrophage function, including macrophage activation, phagocytosis, and efferocytosis. Our data suggests that exposing macrophages to HA<sup>HMW</sup> pushes macrophages toward a more pro-inflammatory phenotype as indicated by increased secretion of pro-inflammatory signals such as IL-2, IL-17, and IP-10<em>.</em> Our data also suggests that in the presence of HA, both macrophage efferocytosis and Fc-receptor dependent phagocytosis are suppressed. These results are unique to treatment with HA<sup>HMW</sup>, as similar results were not observed when cells were treated with HA<sup>LMW</sup>. Using macrophages from <em>Cd44</em><sup><em>−/−</em></sup> mice, we determined that while the impact of HA<sup>HMW</sup> on cytokine secretion does seem to be dependent in part on <em>Cd44</em> expression, the impact on macrophage phagocytosis is independent. Since macrophage efferocytosis of dying cardiomyocytes and cellular debris is critical following MI, we believe that this response will prolong the resolution of inflammation and lead to maladaptive remodeling.</div></div><div><h3>Conclusion</h3><div>HA accumulates post-MI and may promote a pro-inflammatory phenotype in macrophages. Future studies will explore the extent to which post infarct HA accumulation regulates cardiac macrophage dynamics and function <em>in vivo</em>.</div></div>","PeriodicalId":16402,"journal":{"name":"Journal of molecular and cellular cardiology","volume":"198 ","pages":"Pages 24-35"},"PeriodicalIF":4.9,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of molecular and cellular cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1